Wolff Financial Management LLC acquired a new position in shares of Amgen, Inc. (NASDAQ:AMGN) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,162 shares of the medical research company’s stock, valued at approximately $214,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Capital Financial Planning LLC acquired a new position in Amgen during the 4th quarter valued at approximately $27,000. Arbor Wealth Management LLC increased its stake in Amgen by 154.5% during the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 102 shares in the last quarter. Next Capital Management LLC acquired a new position in Amgen during the 4th quarter valued at approximately $33,000. C J Advisory Inc acquired a new position in Amgen during the 1st quarter valued at approximately $40,000. Finally, Clarfeld Financial Advisors LLC acquired a new position in Amgen during the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 77.50% of the company’s stock.
In related news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at $3,064,306.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.25% of the company’s stock.
Shares of NASDAQ:AMGN traded up $1.22 during midday trading on Friday, reaching $187.22. The company’s stock had a trading volume of 2,963,649 shares, compared to its average volume of 2,814,827. The firm has a market capitalization of $111.54 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 2.22 and a beta of 1.19. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $210.19. The firm has a fifty day moving average price of $180.90. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.53.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.83 earnings per share. Equities analysts predict that Amgen, Inc. will post 14.23 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.10%. Amgen’s payout ratio is currently 40.28%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.